PMID- 36510261
OWN - NLM
STAT- MEDLINE
DCOM- 20221214
LR  - 20221222
IS  - 1742-2094 (Electronic)
IS  - 1742-2094 (Linking)
VI  - 19
IP  - 1
DP  - 2022 Dec 12
TI  - Impact of disease-modifying therapy on dendritic cells and exploring their 
      immunotherapeutic potential in multiple sclerosis.
PG  - 298
LID - 10.1186/s12974-022-02663-z [doi]
LID - 298
AB  - Dendritic cells (DCs) are the most potent professional antigen-presenting cells 
      (APCs), which play a pivotal role in inducing either inflammatory or tolerogenic 
      response based on their subtypes and environmental signals. Emerging evidence 
      indicates that DCs are critical for initiation and progression of autoimmune 
      diseases, including multiple sclerosis (MS). Current disease-modifying therapies 
      (DMT) for MS can significantly affect DCs' functions. However, the study on the 
      impact of DMT on DCs is rare, unlike T and B lymphocytes that are the most 
      commonly discussed targets of these therapies. Induction of tolerogenic DCs 
      (tolDCs) with powerful therapeutic potential has been well-established to combat 
      autoimmune responses in laboratory models and early clinical trials. In contrast 
      to in vitro tolDC induction, in vivo elicitation by specifically targeting 
      multiple cell-surface receptors has shown greater promise with more advantages. 
      Here, we summarize the role of DCs in governing immune tolerance and in the 
      process of initiating and perpetuating MS as well as the effects of current DMT 
      drugs on DCs. We then highlight the most promising cell-surface receptors 
      expressed on DCs currently being explored as the viable pharmacological targets 
      through antigen delivery to generate tolDCs in vivo.
CI  - (c) 2022. The Author(s).
FAU - Liu, Caiyun
AU  - Liu C
AUID- ORCID: 0000-0002-3724-5840
AD  - Neuroscience Center, Department of Neurology, The First Hospital of Jilin 
      University, Changchun, China.
FAU - Zhu, Jie
AU  - Zhu J
AUID- ORCID: 0000-0003-4910-2828
AD  - Neuroscience Center, Department of Neurology, The First Hospital of Jilin 
      University, Changchun, China.
AD  - Department of Neurobiology, Care Sciences & Society, Division of Neurogeriatrcs, 
      Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden.
FAU - Mi, Yan
AU  - Mi Y
AUID- ORCID: 0000-0002-5222-2903
AD  - Neuroscience Center, Department of Neurology, The First Hospital of Jilin 
      University, Changchun, China.
FAU - Jin, Tao
AU  - Jin T
AUID- ORCID: 0000-0002-7028-3419
AD  - Neuroscience Center, Department of Neurology, The First Hospital of Jilin 
      University, Changchun, China. jin_tao@jlu.edu.cn.
LA  - eng
GR  - 82171337/National Natural Science Foundation of China/
GR  - 20190201043JC/Natural Science Foundation of Jilin Province/
GR  - JLSWSRCZX2020-0056/Department of Finance of Jilin Province/
GR  - JJKH20211204KJ/Education Department of Jilin Province/
PT  - Journal Article
PT  - Review
DEP - 20221212
PL  - England
TA  - J Neuroinflammation
JT  - Journal of neuroinflammation
JID - 101222974
SB  - IM
MH  - Humans
MH  - *Multiple Sclerosis/therapy
MH  - Dendritic Cells
MH  - Immune Tolerance
MH  - *Autoimmune Diseases
MH  - *Ichthyosiform Erythroderma, Congenital
PMC - PMC9743681
OTO - NOTNLM
OT  - Dendritic cell
OT  - Immunotherapy
OT  - Multiple sclerosis
OT  - Tolerance
COIS- The authors declare that they have no competing interests.
EDAT- 2022/12/13 06:00
MHDA- 2022/12/15 06:00
PMCR- 2022/12/12
CRDT- 2022/12/12 23:51
PHST- 2022/06/28 00:00 [received]
PHST- 2022/12/01 00:00 [accepted]
PHST- 2022/12/12 23:51 [entrez]
PHST- 2022/12/13 06:00 [pubmed]
PHST- 2022/12/15 06:00 [medline]
PHST- 2022/12/12 00:00 [pmc-release]
AID - 10.1186/s12974-022-02663-z [pii]
AID - 2663 [pii]
AID - 10.1186/s12974-022-02663-z [doi]
PST - epublish
SO  - J Neuroinflammation. 2022 Dec 12;19(1):298. doi: 10.1186/s12974-022-02663-z.